ESCKX Mutual Fund

ESCKX Mutual Fund

NAV$16.46
See how much of ESCKX you already own
Just $25 once·$99/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of Aug 31, 2026

Net Assets
$310,394.3
Expense Ratio
1.38%
Dividend Yield (Current)
-
Holdings
102
Inception Date
Jul 11, 2022
Fund Family
1290 Funds
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO

Performance

YTD+5.04%
1 Year+3.41%
3 Year+26.17%

Asset Allocation

Stocks: 96.53%
Cash: 2.59%
Other: 0.89%
See how much of ESCKX you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report comes with FundXLS. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
KNSAKiniksa Pharmaceuticals, Ltd.2.74%
ADPTAdaptive Biotechnologies2.45%
JIMXXJpmorgan Prime Money2.33%
CECOCeco Environmental Corp Common Stock Usd 0.012.24%
TVTXTravere Therapeutics Inc1.97%
Top 10 Concentration: 20.22%Report Date: Aug 31, 2026
Download all 102 holdings for ESCKX
CSV export with sector, industry & share changes
Get CSV

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

ESCKX Mutual Fund Overview

ESCKX Mutual Fund (1290 Essex Small Cap Growth Fund Class R) is managed by 1290 Funds with $310,394.3 in net assets. ESCKX expense ratio is 1.38%, holding 102 positions across sectors including Information Technology, Industrials, Health Care. Inception date: 2022-07-11.

ESCKX performance shows a YTD return of 5.04%. The 1-year return is 3.41%.

ESCKX top holdings include Kiniksa Pharmaceuticals, Ltd. (2.7%), Adaptive Biotechnologies (2.5%), Jpmorgan Prime Money (2.3%), Ceco Environmental Corp Common Stock Usd 0.01 (2.2%), Travere Therapeutics Inc (2.0%). Go to all ESCKX holdings, ESCKX sectors, or ESCKX dividends.

ESCKX can be compared against other funds. Use ESCKX overlap to find shared positions, or ESCKX vs another fund for a side-by-side view. ESCKX alternatives are available via the screener, along with tax-loss harvesting opportunities.